Literature DB >> 32092363

Cystoid macular edema related to cataract surgery and topical prostaglandin analogs: Mechanism, diagnosis, and management.

Gábor Holló1, Tin Aung2, Louis B Cantor3, Makoto Aihara4.   

Abstract

Cystoid macular edema (CME) is a form of macular retina thickening that is characterized by the appearance of cystic fluid-filled intraretinal spaces. It has classically been diagnosed upon investigation after a decrease in visual acuity; however, improvements in imaging technology make it possible to noninvasively detect CME even before a clinically significant decrease in central vision. Risk factors for the development of CME include diabetic retinopathy, retinal vein occlusion, uveitis, and cataract surgery. It has been proposed that eyes with elevated intraocular pressure after cataract surgery, including those treated with prostaglandin analog eye drops, may be at higher risk for the development of CME. We summarize the current knowledge of the molecular mechanisms underlying CME, the potential role of ocular surgery and topical glaucoma medication in increasing the risk of CME, the newly developed imaging methods for diagnosing CME, and the clinical management of CME.
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  bimatoprost; elevated intraocular pressure; glaucoma and cataract surgery; latanoprost; omidenepag isopropyl; postoperative complications; prostaglandin analogs; pseudophakic cystoid macular edema; tafluprost; travoprost

Mesh:

Substances:

Year:  2020        PMID: 32092363     DOI: 10.1016/j.survophthal.2020.02.004

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  19 in total

Review 1.  Prostanoid receptor agonists for glaucoma treatment.

Authors:  Makoto Aihara
Journal:  Jpn J Ophthalmol       Date:  2021-07-06       Impact factor: 2.447

2.  Twelve-month efficacy and safety of omidenepag isopropyl, a selective EP2 agonist, in open-angle glaucoma and ocular hypertension: the RENGE study.

Authors:  Makoto Aihara; Fenghe Lu; Hisashi Kawata; Akihiro Iwata; Noriko Odani-Kawabata
Journal:  Jpn J Ophthalmol       Date:  2021-09-08       Impact factor: 2.447

3.  Changes in the peripapillary vasculature and macular thickness after cataract surgery using two phacoemulsification systems with optical coherence tomography angiography.

Authors:  Liang-Zhang Tan; Fang Tian; Lu Chen; Li-Na Sun; Xue Gong; Jing-Li Liang; Hong Zhang; Xiao-Rong Li
Journal:  Int J Ophthalmol       Date:  2022-06-18       Impact factor: 1.645

Review 4.  Effects and Prognosis of Cataract Surgery in Patients with Retinitis Pigmentosa.

Authors:  Hailong He; Hao Song; Xiaodie Meng; Kai Cao; Yi-Xin Liu; Jinda Wang; Xiuhua Wan; Zi-Bing Jin
Journal:  Ophthalmol Ther       Date:  2022-09-04

Review 5.  Cystoid macular oedema without leakage in fluorescein angiography: a literature review.

Authors:  Masood Naseripour; Sara Hemmati; Samira Chaibakhsh; Arzhang Gordiz; Leila Miri; Fatemeh Abdi
Journal:  Eye (Lond)       Date:  2022-09-10       Impact factor: 4.456

6.  Macular and Optic Disc Parameters in Children with Amblyopic and Nonamblyopic Eyes under Optical Coherence Tomography Fundus Images.

Authors:  Dan Zhu; Qiang Sun; Hong Yang; Yangcheng Zou; Chunmei Liu; Yan Xu
Journal:  Comput Math Methods Med       Date:  2022-06-15       Impact factor: 2.809

7.  A Real-World Study of Dexamethasone Implant in Treatment-Naïve Patients with Diabetic Macular Edema: Efficacy and Correlation Between Inflammatory Biomarkers and Treatment Outcome.

Authors:  Maria Vadalà; Valentina Sunseri Trapani; Giulia Guarrasi; Nicasio Ventura; Massimo Castellucci; Salvatore Cillino
Journal:  Clin Ophthalmol       Date:  2020-09-15

8.  Short-Term Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma.

Authors:  Kenji Inoue; Junji Inoue; Shiho Kunimatsu-Sanuki; Norie Nozaki; Kosuke Shimizu; Kyoko Ishida; Goji Tomita
Journal:  Clin Ophthalmol       Date:  2020-09-30

Review 9.  Efficacy and Patient Tolerability of Omidenepag Isopropyl in the Treatment of Glaucoma and Ocular Hypertension.

Authors:  Masato Matsuo; Yotaro Matsuoka; Masaki Tanito
Journal:  Clin Ophthalmol       Date:  2022-04-26

10.  Omidenepag, a non-prostanoid EP2 receptor agonist, induces enlargement of the 3D organoid of 3T3-L1 cells.

Authors:  Yosuke Ida; Fumihito Hikage; Araya Umetsu; Haruka Ida; Hiroshi Ohguro
Journal:  Sci Rep       Date:  2020-09-29       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.